Smoking and antidepressants pharmacokinetics: A systematic review

Annals of General Psychiatry

Volumn 16, Issue 1, 2017, Pages

  Oliveira, Pedro ^a   Ribeiro, Joana ^a   Donato, Helena ^a   Madeira, Nuno ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Antidepressant agents; Depressive disorder; Pharmacokinetics; Smoking

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; REVIEW; SMOKING; SMOKING HABIT; SYSTEMATIC REVIEW;

EID: 85014551822     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/s12991-017-0140-8     Document Type: Review

References (36)

1. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149(9):1189-94.
2. Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry. 2010;23:112-9.
3. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.
4. Bastos H, Polido F, Saraiva C. História da Psiquiatria. In: Saraiva C, Cerejeira J, editors. Psiquiatria fundamental. Coimbra: Lidel Edições Técnicas; 2014.
5. Haji EO, Hiemke C, Pfuhlmann B. Therapeutic drug monitoring for antidepressant drug treatment. Curr Pharm Des. 2012;18(36):5818-27.
6. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63:437-59.
7. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195-235.
8. Kim YH, Bae YJ, Kim HS, Cha HJ, Yun JS, Shin JS, et al. Measurement of human cytochrome P450 enzyme induction based on mesalazine and mosapride citrate treatments using a luminescent assay. Biomol Ther. 2015;23(5):486-92.
9. Zevin S, Benowitz N. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999;36(6):425-38.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group: preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3:123-30.
11. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration. 2011. http://www.cochrane-handbook.org. Accessed June 2016.
12. Lundmark J, Margareta R, Finn B. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit. 2001;23:139-47.
13. Koelch M, Pfalzer A, Kliegl K, Rothenhöfer S, Ludolph AG, Fegert JM, et al. Therapeutic drug monitoring of children and adolescents treated with fluoxetine. Pharmacopsychiatry. 2012;45:72-6.
14. Lundmark J, Margareta R, Finn B. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-54.
15. Taurines R, Burger R, Wewetzer C, Pfuhlmann B, Mehler-Wex C, Gerlach M, et al. The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: a naturalistic study. Ther Drug Monit. 2013;35:84-91.
16. Reis M, Cherma M, Carlsson B, Bengtsson F. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit. 2007;29:758-66.
17. Reis M, Olson G, Carlsson B, Bengtsson F. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol. 2002;22:406-13.
18. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther. 1995;4:399-403.
19. Carrillo J, Dahl M, Svensson J, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther. 1996;2:183-90.
20. Yoshimura R, Ueda N, Jun Nakamura J, Eto S, Matsushita M. Interaction between fluvoxamine and cotinine or caffeine. Neuropsychobiology. 2002;45:32-5.
21. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, et al. Effects of the CYP 2d6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit. 2003;25:463-8.
22. Sugahara H, Maebara C, Ohtani H, Handa M, Ando K, Mine K, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. Eur J Clin Pharmacol. 2009;65:699-704.
23. Katoh Y, Uchida S, Kawai M, Takei N, Mori N, Kawakami J, et al. Effects of cigarette smoking and cytochrome p450 2d6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull. 2010;33:285-8.
24. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Inoue Y, et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol. 2011;25:908-14.
25. Reis M, Lundmark J, Bjork H, Bengtsson F. therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit. 2002;24:545-53.
26. Unterecker S, Hiemke C, Greiner C, Haen E, Jabs B, Deckert J, et al. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and o-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry. 2012;45:229-35.
27. Fric M, Pfuhlmann B, Laux G, Riederer P, Distler G, Artmann S, et al. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry. 2008;41:151-5.
28. Lobo E, Quinlan T, O'Brien L, Knadler MP, Heathman M. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet. 2009;48:189-97.
29. Ishida M, Otani K, Kaneko S, Ohkubo T, Osanai T, Yasui N, Mihara K, Higuchi H, Sugawara K. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol. 1995;10(3):143-6.
30. Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, Ahlner J, et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet. 2009;48(1):63-70.
31. Sirot EJ, Harenberg S, Vandel P, Lima CA, Perrenoud P, Kemmerling K, et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol. 2012;32(5):622-9.
32. Hsyu PH, Singh A, Giargiari TD, Dunn JA, Ascher JA, Johnston JA. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol. 1997;37(8):737-43.
33. Sandson NB. Drug interactions casebook: the cytochrome P450 system and beyond. Chicago: American Psychiatric Publishing; 2003.
34. Muth E, Moyer J, Haskins J, Andree TH, Husbands GM. Biochemical, neurophysiological, and behavioral effects of wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23:191-9.
35. Monteleone P, Gnocchi G, Delrio G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. J Clin Psychopharmacol. 1989;9(4):284-7.
36. Grasmäder K, Verwohlt PL, Kühn KU, Frahnert C, Hiemke C, Dragicevic A, et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry. 2005;38(3):113-7.